Early clozapine discontinuation: who is at risk?
- Conditions
- Psychotic disorders, Schizophrenia, Schizoaffective disordersPsychotische stoornissen,Schizofrenie, Schizoaffectieve stoornissen
- Registration Number
- NL-OMON20555
- Lead Sponsor
- Division of Pharmacoepidemiology & Clinical Pharmacology of the Department of Pharmaceutical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All patients, aged 18 years or older, of whom demographical, medical and social data are registered in the AHD and the PCR-MN, between 2001 and 2014, who have been prescribed clozapine are eligible for the study.
Exclusion Criteria
-the absence of any drug-dispensing records over the past two years before introduction of clozapine.
-the absence of drug-dispensing data of any drug in the 12 weeks after cessation of clozapine, if applicable,
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Discontinuation of clozapine use within one year after the start is the main outcome measure.
- Secondary Outcome Measures
Name Time Method Discontinuation of clozapine use within 6 months after the start is the main outcome measure.